This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 288 |
respiratory syndrome | 253 |
novel coronavirus | 201 |
severe acute | 200 |
respiratory tract | 159 |
cord uid | 149 |
doc id | 149 |
infect doi | 149 |
coronavirus disease | 122 |
syndrome coronavirus | 121 |
infectious diseases | 107 |
respiratory viruses | 105 |
ifn lambda | 95 |
kawasaki disease | 95 |
intensive care | 94 |
clinical characteristics | 93 |
zika virus | 90 |
public health | 89 |
cmv dna | 89 |
virus infection | 84 |
clinical features | 84 |
nucleic acid | 82 |
lower respiratory | 81 |
hong kong | 78 |
risk factors | 78 |
middle east | 76 |
high risk | 76 |
viral load | 76 |
falciparum malaria | 74 |
influenza virus | 72 |
east respiratory | 68 |
respiratory syncytial | 66 |
respiratory virus | 66 |
children aged | 65 |
severe pneumonia | 64 |
critically ill | 64 |
syncytial virus | 64 |
systematic review | 64 |
severe covid | 61 |
iu ml | 59 |
respiratory distress | 57 |
bal fluid | 57 |
acquired pneumonia | 57 |
disease severity | 57 |
cov infection | 55 |
chain reaction | 55 |
respiratory failure | 55 |
infection control | 54 |
among children | 54 |
polymerase chain | 54 |
human bocavirus | 53 |
like illness | 53 |
viral infections | 52 |
human coronavirus | 52 |
per cent | 52 |
avian influenza | 51 |
world health | 51 |
health care | 51 |
infectious disease | 50 |
nasopharyngeal swab | 49 |
united states | 49 |
cohort study | 48 |
ill patients | 48 |
coronavirus infection | 48 |
healthcare workers | 47 |
respiratory infections | 46 |
respiratory illness | 45 |
severe patients | 45 |
zikv infection | 45 |
aged years | 45 |
severe malaria | 44 |
distress syndrome | 44 |
care unit | 43 |
present study | 43 |
patients infected | 43 |
influenza vaccination | 42 |
years old | 41 |
influenza pandemic | 40 |
infected patients | 40 |
mechanical ventilation | 40 |
sars patients | 40 |
severe disease | 40 |
disease control | 39 |
tract infections | 39 |
cmv pneumonia | 39 |
clinical course | 39 |
pcr assays | 39 |
respiratory symptoms | 39 |
fluid specimens | 39 |
viral infection | 38 |
reference standard | 38 |
mortality rate | 38 |
influenza infection | 38 |
human metapneumovirus | 37 |
symptom onset | 37 |
cancer patients | 37 |
performed using | 37 |
hospital admission | 37 |
health organization | 37 |
young children | 36 |
hospitalized patients | 36 |
time pcr | 36 |
immune response | 35 |
reactive protein | 35 |
statistically significant | 35 |
chest ct | 35 |
pulmonary disease | 34 |
coronavirus pneumonia | 34 |
control measures | 34 |
viral pneumonia | 34 |
informed consent | 34 |
significantly higher | 34 |
general population | 34 |
serum samples | 34 |
upper respiratory | 34 |
predictive factors | 34 |
mycophenolic acid | 34 |
viral loads | 33 |
confirmed cases | 33 |
respiratory viral | 33 |
positive results | 33 |
among patients | 32 |
respiratory infection | 32 |
influenza vaccine | 32 |
chronic obstructive | 32 |
sars coronavirus | 32 |
virus infections | 32 |
swab samples | 32 |
related pneumonia | 31 |
influenza viruses | 31 |
authors declare | 31 |
obstructive pulmonary | 31 |
seven days | 31 |
diagnostic tests | 31 |
severely ill | 31 |
severe illness | 30 |
tract infection | 30 |
oxygen saturation | 30 |
clinical management | 30 |
supplementary table | 29 |
significant difference | 29 |
emergency department | 29 |
reverse transcription | 29 |
type iii | 29 |
pcr testing | 29 |
pandemic influenza | 29 |
sore throat | 29 |
test performance | 28 |
previously described | 28 |
pcr assay | 28 |
i group | 28 |
risk group | 28 |
bacterial pneumonia | 28 |
risk factor | 28 |
increased risk | 27 |
viral rna | 27 |
liver injury | 26 |
primary care | 26 |
patients admitted | 26 |
hospitalised patients | 26 |
streptococcus pneumoniae | 26 |
face mask | 25 |
pneumonia development | 25 |
mean age | 25 |
clinical symptoms | 25 |
phylogenetic analysis | 25 |
neutralizing antibody | 25 |
may also | 25 |
clinical outcomes | 25 |
respiratory rate | 25 |
bacterial infection | 24 |
closely related | 24 |
cytokine storm | 24 |
converting enzyme | 24 |
dna load | 24 |
retrospective cohort | 24 |
incubation period | 24 |
coronavirus infections | 24 |
otitis media | 24 |
bronchoalveolar lavage | 24 |
patients without | 24 |
age groups | 24 |
viral shedding | 24 |
severe cases | 24 |
saudi arabia | 24 |
logistic regression | 24 |
controlled trial | 23 |
respiratory specimens | 23 |
elderly patients | 23 |
pregnant women | 23 |
median age | 23 |
previous studies | 23 |
influenza patients | 23 |
yn im | 23 |
test results | 23 |
clinical manifestations | 23 |
chronic diarrhoea | 23 |
pcr results | 23 |
meningococcal disease | 23 |
south korea | 23 |
diagnostic test | 22 |
within days | 22 |
study group | 22 |
united kingdom | 22 |
staphylococcus aureus | 22 |
pneumococcal disease | 22 |
retrospective study | 22 |
clinical trial | 22 |
significantly associated | 22 |
factors associated | 22 |
multiplex pcr | 22 |
predictive value | 22 |
antiviral therapy | 22 |
neutralizing antibodies | 21 |
clinical trials | 21 |
cell culture | 21 |
amino acid | 21 |
epithelial cells | 21 |
oxygen therapy | 21 |
neuraminidase inhibitors | 21 |
gold standard | 21 |
icu patients | 21 |
negative results | 21 |
patients received | 21 |
transplant recipients | 21 |
case series | 21 |
higher risk | 21 |
new coronavirus | 21 |
ill covid | 21 |
health protection | 21 |
age group | 20 |
study period | 20 |
confirmed covid | 20 |
ethics committee | 20 |
rotavirus gastroenteritis | 20 |
stem cell | 20 |
diagnostic accuracy | 20 |
positive rate | 20 |
patients may | 20 |
bacterial pathogens | 20 |
prospective study | 20 |
continuous variables | 20 |
time reverse | 19 |
included patients | 19 |
pneumoniae colonization | 19 |
novel human | 19 |
acute lower | 19 |
seasonal influenza | 19 |
guangdong province | 19 |
observational study | 19 |
clinical specimens | 19 |
exact test | 19 |
descriptive study | 19 |
performance characteristics | 19 |
second wave | 19 |
spike protein | 19 |
coronavirus hku | 19 |
nasopharyngeal swabs | 19 |
primary viral | 19 |
pneumocystis jirovecii | 19 |
healthy children | 19 |
risk groups | 18 |
ct values | 18 |
antibody response | 18 |
close contact | 18 |
hospitalized children | 18 |
electron microscopy | 18 |
ng ml | 18 |
control subjects | 18 |
tested positive | 18 |
receptor binding | 18 |
close contacts | 18 |
rhinovirus enterovirus | 18 |
inflammatory response | 18 |
nervous system | 18 |
associated coronavirus | 18 |
ground glass | 18 |
throat swabs | 18 |
multivariate analysis | 18 |
positive samples | 18 |
blood donors | 18 |
neural network | 18 |
two groups | 18 |
pao fio | 18 |
care workers | 18 |
saliva samples | 18 |
zika fever | 18 |
sars cov | 18 |
respiratory samples | 18 |
antibiotic treatment | 18 |
global health | 17 |
laboratory tests | 17 |
two patients | 17 |
community acquired | 17 |
septic shock | 17 |
critical patients | 17 |
immune responses | 17 |
critically severe | 17 |
blood cells | 17 |
respiratory disease | 17 |
liver disease | 17 |
kawasaki syndrome | 17 |
rsv infection | 17 |
small number | 17 |
mg kg | 17 |
sample size | 17 |
first case | 17 |
critical care | 17 |
severe respiratory | 17 |
dengue fever | 17 |
virus detection | 17 |
three days | 17 |
antibiotic therapy | 17 |
human rhinovirus | 17 |
day mortality | 17 |
case report | 17 |
infection rate | 17 |
ili episodes | 17 |
human respiratory | 17 |
positive cases | 17 |
parainfluenza virus | 16 |
yellow fever | 16 |
igg antibodies | 16 |
important role | 16 |
intravenous artesunate | 16 |
false negative | 16 |
secondary bacterial | 16 |
older children | 16 |
gene expression | 16 |
antiviral treatment | 16 |
previous study | 16 |
patients presenting | 16 |
early stage | 16 |
inclusion criteria | 16 |
generation sequencing | 16 |
statistical significance | 16 |
total number | 16 |
genome sequences | 16 |
written informed | 16 |
renal failure | 16 |
antimicrobial therapy | 16 |
breast milk | 16 |
pcr positivity | 16 |
mscs therapy | 16 |
clinical diagnosis | 16 |
household members | 16 |
blood culture | 16 |
mg ml | 16 |
health organisation | 16 |
positive patients | 16 |
study showed | 16 |
confidence interval | 16 |
body temperature | 16 |
competing interests | 16 |
central nervous | 16 |
university hospital | 16 |
family cluster | 16 |
dna loads | 16 |
times higher | 16 |
odds ratio | 16 |
previous reports | 15 |
ct value | 15 |
case definitions | 15 |
may present | 15 |
function tests | 15 |
infected infants | 15 |
heart rate | 15 |
regression analysis | 15 |
significant differences | 15 |
human transmission | 15 |
clinical data | 15 |
coronary artery | 15 |
two studies | 15 |
pneumoniae carriage | 15 |
recent study | 15 |
previously reported | 15 |
severe falciparum | 15 |
cerebrospinal fluid | 15 |
mainland china | 15 |
risk influenza | 15 |
bal specimens | 15 |
two days | 15 |
vaccination coverage | 15 |
innate immune | 15 |
high proportion | 15 |
ct scanning | 15 |
oropharyngeal swab | 15 |
stool samples | 15 |
fatality rate | 15 |
news score | 15 |
significantly different | 15 |
patient care | 15 |
categorical variables | 15 |
copies ml | 15 |
case definition | 15 |
severity assessment | 15 |
detection rate | 15 |
data collection | 15 |
blood samples | 15 |
among healthcare | 15 |
liver function | 15 |
gastrointestinal symptoms | 14 |
case reports | 14 |
national health | 14 |
care units | 14 |
immunocompromised patients | 14 |
white blood | 14 |
two cases | 14 |
epidemiological characteristics | 14 |
glass opacity | 14 |
risk genotypes | 14 |
severe infection | 14 |
iii ifn | 14 |
gattii sensu | 14 |
per day | 14 |
plasmodium vivax | 14 |
mg dl | 14 |
study design | 14 |
vivax malaria | 14 |
randomised controlled | 14 |
genetic diversity | 14 |
infected pneumonia | 14 |
recurrent positive | 14 |
breaths min | 14 |
independent risk | 14 |
much higher | 14 |
mild illness | 14 |
vero cells | 14 |
cell responses | 14 |
patients treated | 14 |
one week | 14 |
hospital stay | 14 |
vital signs | 14 |
pcr test | 14 |
diagnostic testing | 14 |
corticosteroid treatment | 14 |
lung disease | 14 |
respiratory pathogens | 14 |
medical records | 14 |
highly pathogenic | 14 |
peripheral blood | 14 |
severe critical | 14 |
tertiary care | 13 |
control patients | 13 |
phylogenetic trees | 13 |
within hours | 13 |
associated hospitalization | 13 |
pcr tests | 13 |
bacterial infections | 13 |
hrv infection | 13 |
tract samples | 13 |
least one | 13 |
among hcp | 13 |
disease progression | 13 |
vp gene | 13 |
sensu stricto | 13 |
surveillance data | 13 |
randomized controlled | 13 |
one study | 13 |
year old | 13 |
protective equipment | 13 |
based strategy | 13 |
blood pressure | 13 |
broad spectrum | 13 |
recombination events | 13 |
pneumonia patients | 13 |
one year | 13 |
potential role | 13 |
antibody titers | 13 |
total population | 13 |
health commission | 13 |
clinical findings | 13 |
antibiotic prophylaxis | 13 |
early warning | 13 |
cryptococcus gattii | 13 |
cd cell | 13 |
children hospitalized | 13 |
mers outbreak | 13 |
french polynesia | 13 |
codon variant | 13 |
normal control | 13 |
face masks | 13 |
influenza outpatient | 13 |
febrile pharyngitis | 13 |
infection among | 13 |
clinical practice | 13 |
pneumonia cases | 13 |
causative agent | 13 |
transcription polymerase | 13 |
study clinical | 13 |
recent studies | 13 |
aged months | 13 |
priority group | 13 |
see appendix | 13 |
clinical outcome | 13 |
coronavirus oc | 13 |
two weeks | 13 |
review board | 13 |
statistical analysis | 12 |
large number | 12 |
common cold | 12 |
healthy controls | 12 |
pandemic flu | 12 |
disease caused | 12 |
one case | 12 |
eculizumab recipients | 12 |
carriage rates | 12 |
chest radiograph | 12 |
dry cough | 12 |
determine whether | 12 |
five days | 12 |
antimicrobial susceptibility | 12 |
serological testing | 12 |
mild patients | 12 |
side effects | 12 |
specific grant | 12 |
also found | 12 |
infection rates | 12 |
intravenous immunoglobulin | 12 |
endemic areas | 12 |
first wave | 12 |
significantly increased | 12 |
imported cases | 12 |
univariate analysis | 12 |
may require | 12 |
acid amplification | 12 |
confidence intervals | 12 |
antibody detection | 12 |
complicated malaria | 12 |
exposure history | 12 |
nucleocapsid protein | 12 |
prognostic factors | 12 |
novel genotype | 12 |
positive rt | 12 |
false positive | 12 |
patients died | 12 |
recent report | 12 |
clustering algorithm | 12 |
wide range | 12 |
pediatric patients | 12 |
diseases society | 12 |
detect sars | 12 |
profit sectors | 12 |
heart disease | 12 |
corticosteroid therapy | 12 |
antibody responses | 12 |
mbl codon | 12 |
significant association | 12 |
west nile | 12 |
patients receiving | 12 |
imported malaria | 12 |
ct scan | 12 |
children younger | 12 |
african swine | 12 |
control group | 12 |
statistical analyses | 12 |
human coronaviruses | 12 |
japanese encephalitis | 12 |
dear editor | 12 |
swine fever | 12 |
intravenous quinine | 12 |
ct imaging | 12 |
medical workers | 12 |
clinical deterioration | 12 |
blood mxa | 12 |
nasal swabs | 11 |
rgd kgd | 11 |
human infection | 11 |
antibiotic use | 11 |
acid test | 11 |
nasopharyngeal washings | 11 |
haemolytic streptococci | 11 |
mycoplasma pneumoniae | 11 |
iii ifns | 11 |
positive result | 11 |
clinical presentation | 11 |
sample collection | 11 |
risk assessment | 11 |
illness onset | 11 |
higher mortality | 11 |
supplementary material | 11 |
clinical impact | 11 |
laboratory results | 11 |
rapid detection | 11 |
immune system | 11 |
cell count | 11 |
vaccination rate | 11 |
heart failure | 11 |
person transmission | 11 |
uncomplicated falciparum | 11 |
funding agencies | 11 |
institutional review | 11 |
antibody test | 11 |
one patient | 11 |
chronic diseases | 11 |
personal protective | 11 |
frequently detected | 11 |
linked immunosorbent | 11 |
bat origin | 11 |
asymptomatic patients | 11 |
acute encephalitis | 11 |
cov infected | 11 |
hiv infection | 11 |
uk alert | 11 |
gg genotype | 11 |
future studies | 11 |
tested negative | 11 |
controlled trials | 11 |
patients hospitalized | 11 |
suspected cases | 11 |
red blood | 11 |
isothermal amplification | 11 |
igm antibodies | 11 |
lavage fluid | 11 |
pathogen detection | 11 |
interquartile range | 11 |
hematopoietic stem | 11 |
haemophilus influenzae | 11 |
pcr positive | 11 |
see section | 11 |
limited number | 11 |
clinical severity | 11 |
household transmission | 11 |
cell transplant | 11 |
acid testing | 11 |
hbov infection | 11 |
relatively high | 11 |
nsp nsp | 11 |
asian countries | 11 |
acid detection | 11 |
microbiological investigations | 11 |
least days | 11 |
medical conditions | 11 |
respiratory droplets | 11 |
common respiratory | 11 |
treated patients | 11 |
infectious bronchitis | 11 |
three cases | 11 |
also observed | 11 |
observational cohort | 11 |
south america | 11 |
pulmonary tuberculosis | 11 |
isolate patients | 11 |
cells mm | 11 |
pulmonary function | 10 |
three studies | 10 |
oropharyngeal swabs | 10 |
viral entry | 10 |
natural science | 10 |
lung injury | 10 |
binding lectin | 10 |
total cohort | 10 |
virus disease | 10 |
influenzarelated pneumonia | 10 |
infection caused | 10 |
developing countries | 10 |
disease outbreaks | 10 |
invasive pneumococcal | 10 |
reverse transcriptase | 10 |
congenital zikv | 10 |
immunosorbent assay | 10 |
old man | 10 |
mortality score | 10 |
family members | 10 |
viral clearance | 10 |
science foundation | 10 |
transport medium | 10 |
congenital anomalies | 10 |
literature review | 10 |
pulse oximetry | 10 |
high mortality | 10 |
coping capacity | 10 |
small sample | 10 |
widely used | 10 |
protection agency | 10 |
mtb rif | 10 |
warning score | 10 |
bacterial colonization | 10 |
household contacts | 10 |
standard deviation | 10 |
adult patients | 10 |
mg bd | 10 |
fuzzy clustering | 10 |
twice daily | 10 |
proven cmv | 10 |
potential recombination | 10 |
mortality rates | 10 |
whole blood | 10 |
pneumonia panel | 10 |
molecular epidemiology | 10 |
index case | 10 |
cov activities | 10 |
mycophenolate mofetil | 10 |
heptad repeat | 10 |
high prevalence | 10 |
lactate dehydrogenase | 10 |
acute gastroenteritis | 10 |
confirmed sars | 10 |
clotted blood | 10 |
inflammatory cytokines | 10 |
directly related | 10 |
positive pcr | 10 |
considered statistically | 10 |
infectious agents | 10 |
islas baleares | 10 |
complicating influenza | 10 |
ml clotted | 10 |
cell lines | 10 |
complete genome | 10 |
virus transmission | 10 |
acute medical | 10 |
phylogenetic tree | 10 |
clinical evaluation | 10 |
study hospitals | 10 |
bat coronavirus | 10 |
kgd motif | 10 |
gram stain | 10 |
current study | 10 |
syndromic molecular | 10 |
older age | 10 |
respiratory illnesses | 10 |
influenza season | 10 |
results showed | 10 |
samples collected | 10 |
acute phase | 10 |
emergency departments | 10 |
two months | 10 |
intravenous fluids | 10 |
real time | 10 |
invasive ventilation | 10 |
binding domain | 10 |
clinical samples | 10 |
also significantly | 10 |
national institute | 10 |
escherichia coli | 10 |
type i | 10 |
high level | 10 |
xpert mtb | 10 |
compared using | 10 |
immunodeficiency virus | 10 |
mask use | 10 |
general practitioner | 10 |
tds iv | 10 |
antiviral activity | 10 |
avenida islas | 10 |
interpandemic influenza | 10 |
common cause | 10 |
pleural effusion | 10 |
five patients | 10 |
virus type | 9 |
cytomegalovirus infection | 9 |
nile virus | 9 |
study app | 9 |
asymptomatic infection | 9 |
included studies | 9 |
three patients | 9 |
antibody tests | 9 |
screening system | 9 |
another study | 9 |
glass opacities | 9 |
fatal cases | 9 |
wild boar | 9 |
outside wuhan | 9 |
five years | 9 |
pandemic situation | 9 |
health measures | 9 |
uncomplicated malaria | 9 |
saharan africa | 9 |
positivity rate | 9 |
common reason | 9 |
hubei province | 9 |
sars outbreak | 9 |
rapid diagnostic | 9 |
productive cough | 9 |
like coronavirus | 9 |
cell counts | 9 |
may need | 9 |
attack rate | 9 |
different countries | 9 |
positive sars | 9 |
discharged home | 9 |
fatal outcome | 9 |
per year | 9 |
disease associated | 9 |
pg ml | 9 |
care facilities | 9 |
endothelial dysfunction | 9 |
diabetes mellitus | 9 |
cycle threshold | 9 |
amino acids | 9 |
chest radiographs | 9 |
monocyte chemoattractant | 9 |
jirovecii pneumonia | 9 |
initial symptoms | 9 |
human influenza | 9 |
virus replication | 9 |
data analysis | 9 |
antibody levels | 9 |
million people | 9 |
dengue virus | 9 |
bal fluids | 9 |
new virus | 9 |
first time | 9 |
primary health | 9 |
drug compounds | 9 |
swab specimens | 9 |
cases reported | 9 |
molecular tests | 9 |
comparative analysis | 9 |
getv strains | 9 |
postal address | 9 |
lambda subtypes | 9 |
early diagnosis | 9 |
index test | 9 |
adult inpatients | 9 |
chronic lung | 9 |
vitro anti | 9 |
exclusion criteria | 9 |
icu admission | 9 |
blood cell | 9 |
human immunodeficiency | 9 |
extracorporeal membrane | 9 |
time period | 9 |
urgently needed | 9 |
aspartate aminotransferase | 9 |
antiviral drugs | 9 |
radiological findings | 9 |
viral nucleic | 9 |
blood count | 9 |
high incidence | 9 |
hrv infections | 9 |
vaccine strain | 9 |
acute pharyngitis | 9 |
acute renal | 9 |
transmission dynamics | 9 |
significantly lower | 9 |
viral replication | 9 |
isolation facilities | 9 |
human infections | 9 |
see table | 9 |
consecutive patients | 9 |
antigen tests | 9 |
time rt | 9 |
gene polymorphisms | 9 |
viral culture | 9 |
uk infections | 9 |
chest radiography | 9 |
mortality risk | 9 |
membrane oxygenation | 9 |
cell transplantation | 9 |
based study | 9 |
four days | 9 |
cmv dnaemia | 9 |
first report | 9 |
facial temperature | 9 |
analysis showed | 9 |
reverse primer | 9 |
disease onset | 9 |
old male | 9 |
ambient ozone | 9 |
blood units | 9 |
nasopharyngeal samples | 9 |
high fever | 9 |
acquired infections | 9 |
cn strains | 9 |
calculated using | 9 |
cumulative incidence | 9 |
studies reported | 9 |
animal handlers | 9 |
march th | 9 |
chemoattractant protein | 9 |
children may | 9 |
uncomplicated influenza | 9 |
severe group | 9 |
thoracic society | 9 |
orf ab | 9 |
infants suffering | 9 |
lymphocyte count | 9 |
bocavirus infection | 9 |
old female | 9 |
underlying diseases | 9 |
medical staff | 9 |
oral therapy | 9 |
rotavirus infection | 9 |
origin coronaviruses | 9 |
acute bronchiolitis | 9 |
combination therapy | 9 |
tropical diseases | 9 |
potential infectious | 9 |
nutritional status | 9 |
lambda levels | 9 |
may cause | 9 |
hospital admissions | 9 |
case fatality | 9 |
symptom study | 9 |
immunochromatographic tests | 9 |
local health | 9 |
copd patients | 9 |
infected individuals | 8 |
workers exposed | 8 |
clustering method | 8 |
covid symptom | 8 |
negative predictive | 8 |
growth factor | 8 |
pneumonia outbreak | 8 |
clinical significance | 8 |
mxa levels | 8 |
blood films | 8 |
cd ratio | 8 |
clinical manifestation | 8 |
patients required | 8 |
pneumonia caused | 8 |
cerebral malaria | 8 |
sequence identity | 8 |
swab results | 8 |
getv infection | 8 |
health systems | 8 |
respiratory support | 8 |
hrv bronchiolitis | 8 |
outbreak associated | 8 |
adverse events | 8 |
coronavirus associated | 8 |
probable bat | 8 |
higher levels | 8 |
sputum samples | 8 |
du pont | 8 |
fever virus | 8 |
viral co | 8 |
samples obtained | 8 |
pneumococcal carriage | 8 |
human betacoronavirus | 8 |
travel history | 8 |
probable sars | 8 |
bronchitis virus | 8 |
outside china | 8 |
concomitant infections | 8 |
six months | 8 |
mild group | 8 |
alanine aminotransferase | 8 |
international travel | 8 |
community transmission | 8 |
host cell | 8 |
excess mortality | 8 |
critical group | 8 |
nucleic acids | 8 |
illness among | 8 |
pandemic control | 8 |
global burden | 8 |
hospital referral | 8 |
since december | 8 |
based surveillance | 8 |
vp vp | 8 |
six weeks | 8 |
nipah virus | 8 |
core symptoms | 8 |
well established | 8 |
may develop | 8 |
pediatric medical | 8 |
corona virus | 8 |
lymphocyte ratio | 8 |
risk patients | 8 |
metapneumovirus infection | 8 |
congenital zika | 8 |
infections topics | 8 |
hospital setting | 8 |
illness day | 8 |
zika syndrome | 8 |
symptomatic patients | 8 |
lower lobe | 8 |
th april | 8 |
clinical infectious | 8 |
topics az | 8 |
ks patients | 8 |
parainfluenza viruses | 8 |
four patients | 8 |
tracheal aspirates | 8 |
poor prognosis | 8 |
vertical transmission | 8 |
comorbid conditions | 8 |
oral antibiotics | 8 |
east asia | 8 |
disease association | 8 |
initial presentation | 8 |
throat swab | 8 |
corticosteroids therapy | 8 |
patients will | 8 |
median duration | 8 |
genetic recombination | 8 |
rapid spread | 8 |
virus circulation | 8 |
inspired oxygen | 8 |
commercially available | 8 |
three groups | 8 |
bal sampling | 8 |
emergency room | 8 |
tract illness | 8 |
genome sequence | 8 |
positive blood | 8 |
composite reference | 8 |
respiration rate | 8 |
antimicrobial resistance | 8 |
high rate | 8 |
hbov among | 8 |
related coronavirus | 8 |
laboratory parameters | 8 |
results suggest | 8 |
major cause | 8 |
fio ratio | 8 |
negative control | 8 |
six patients | 8 |
human rhinoviruses | 8 |
study reported | 8 |
adverse effects | 8 |
molecular epidemiological | 8 |
chinese center | 8 |
patient group | 8 |
cd cd | 8 |
pcr result | 8 |
mediated isothermal | 8 |
gastroenteritis patients | 8 |
online version | 8 |
bacterial co | 8 |
moderate covid | 8 |
bat ratg | 8 |
antibiotic resistance | 8 |
organ dysfunction | 8 |
patients requiring | 8 |
getah virus | 8 |
dna shedding | 8 |
large proportion | 8 |
great interest | 8 |
early stages | 8 |
severe sars | 8 |
fever screening | 8 |
study population | 8 |
chronic liver | 8 |
recent years | 8 |
id now | 8 |
national natural | 8 |
health security | 8 |
positive correlation | 8 |
low viral | 8 |
average time | 8 |
diagnostic yield | 8 |
different regions | 8 |
mycobacterium tuberculosis | 8 |
plasmodium falciparum | 8 |
may occur | 8 |
two consecutive | 8 |
aged year | 8 |
lymphocyte counts | 8 |
returned travelers | 8 |
encephalitis virus | 8 |
forward primer | 8 |
antibody testing | 8 |
material associated | 8 |
microbiological investigation | 8 |
also reported | 8 |
stool specimens | 8 |
british infection | 8 |
i groups | 8 |
suspected covid | 8 |
supplementary data | 8 |
many patients | 8 |
hospital discharge | 8 |
potential impact | 8 |
adverse outcomes | 8 |
high levels | 8 |
several limitations | 8 |
associated hospitalizations | 8 |
recently reported | 8 |
corresponding author | 8 |
partial vp | 8 |
disease among | 8 |
clinical evidence | 8 |
medical center | 7 |
mild symptoms | 7 |
healthy people | 7 |
commonly detected | 7 |
center study | 7 |
low level | 7 |
analysis found | 7 |
utilization survey | 7 |
hrv infected | 7 |
prospective cohort | 7 |
viral respiratory | 7 |
scs technology | 7 |
social distancing | 7 |
corticosteroid use | 7 |
hcws exposed | 7 |
alert level | 7 |
susceptibility testing | 7 |
prospective studies | 7 |
next pandemic | 7 |
novel influenza | 7 |
exposure prophylaxis | 7 |
appropriate antibiotics | 7 |
highly effective | 7 |
resistance protein | 7 |
among non | 7 |
gas pharyngitis | 7 |
subclinical infection | 7 |
average age | 7 |
latin america | 7 |
detected viruses | 7 |
laboratory findings | 7 |
respiratory medicine | 7 |
three times | 7 |
probably due | 7 |
flow oxygen | 7 |
cell receptor | 7 |
exclude concomitant | 7 |
specific antibodies | 7 |
pilot study | 7 |
blood gas | 7 |
medical care | 7 |
lung transplant | 7 |
patients showed | 7 |
virus load | 7 |
infected cells | 7 |
adaptive immune | 7 |
critical illness | 7 |
virus particles | 7 |
died within | 7 |
ill children | 7 |
wide association | 7 |
healthy blood | 7 |
enteric pathogens | 7 |
serological tests | 7 |
protein sequences | 7 |
persistent symptoms | 7 |
monkey bites | 7 |
ebola virus | 7 |
imaging features | 7 |
admission levels | 7 |
acute otitis | 7 |
allogeneic hematopoietic | 7 |
coronavirus emc | 7 |
bts guidelines | 7 |
cmv pcr | 7 |
kidney injury | 7 |
immunogenic regions | 7 |
cell sequencing | 7 |
urgent need | 7 |
overall mortality | 7 |
hbv dna | 7 |
wild animals | 7 |
clinical signs | 7 |
virus nucleic | 7 |
returned traveler | 7 |
high altitude | 7 |
natural recombination | 7 |
toxic shock | 7 |
baricitinib therapy | 7 |
age distribution | 7 |
data related | 7 |
global pandemic | 7 |
guangzhou city | 7 |
fluid samples | 7 |
median time | 7 |
patients diagnosed | 7 |
az sars | 7 |
computed tomography | 7 |
lopinavir ritonavir | 7 |
china clinical | 7 |
rna detection | 7 |
study found | 7 |
arti risk | 7 |
nucleotide sequences | 7 |
studies using | 7 |
severe influenza | 7 |
reliable tool | 7 |
extracted data | 7 |
acute influenza | 7 |
angiotensin converting | 7 |
rate min | 7 |
cohort studies | 7 |
case ascertainment | 7 |
seven patients | 7 |
increased susceptibility | 7 |
prior studies | 7 |
hand hygiene | 7 |
current evidence | 7 |
hospitalizations among | 7 |
oc positive | 7 |
effective treatment | 7 |
vaccination among | 7 |
increased levels | 7 |
animal models | 7 |
convalescent plasma | 7 |
cardiac disease | 7 |
mean duration | 7 |
related coronaviruses | 7 |
early identification | 7 |
abdominal pain | 7 |
pneumonia requiring | 7 |
outpatient treatment | 7 |
abbott id | 7 |
applied biosystems | 7 |
means clustering | 7 |
specific cases | 7 |
positive predictive | 7 |
laboratory diagnosis | 7 |
often associated | 7 |
clinical studies | 7 |
ten days | 7 |
viral genomes | 7 |
transcriptase polymerase | 7 |
southern china | 7 |
myxovirus resistance | 7 |
previously healthy | 7 |
quality assessment | 7 |
herpes simplex | 7 |
potential risk | 7 |
developed pneumonia | 7 |
february th | 7 |
associated pneumonia | 7 |
clustered together | 7 |
mg day | 7 |
nt identities | 7 |
full blood | 7 |
home isolation | 7 |
shock syndrome | 7 |
preventive measures | 7 |
bacterial detection | 7 |
high sars | 7 |
least two | 7 |
infection date | 7 |
ct scans | 7 |
like agent | 7 |
analysis using | 7 |
multivariate logistic | 7 |
rapid diagnosis | 7 |
seafood market | 7 |
older agents | 7 |
published studies | 7 |
potential pathogens | 7 |
south east | 7 |
scoping review | 7 |
even though | 7 |
may reflect | 7 |
children human | 7 |
airway tract | 7 |
virus entry | 7 |
per minute | 7 |
predictive factor | 7 |
sequence alignment | 7 |
viral genome | 7 |
clinical presentations | 7 |
five cases | 7 |
recent paper | 7 |
cov activity | 7 |
single center | 7 |
acute hepatitis | 7 |
many countries | 7 |
newly identified | 7 |
taking prophylaxis | 7 |
lactamase stable | 7 |
sputum gram | 7 |
urine antigen | 7 |
dna quantitation | 7 |
isolation precautions | 7 |
older patients | 7 |
within one | 7 |
blood cultures | 7 |
arterial blood | 7 |
infection association | 7 |
study using | 7 |
different parts | 7 |
influenza inpatient | 7 |
adults referred | 7 |
younger age | 7 |
antiviral agents | 7 |
pregnant patients | 7 |
direct contact | 7 |
serum antibodies | 7 |
children less | 7 |
negative controls | 7 |
pulmonary cmv | 7 |
full recovery | 7 |
positive anti | 7 |
subgroup analysis | 7 |
vice versa | 7 |
viruses associated | 7 |
genotype aflp | 7 |
amplification tests | 7 |
continuous evolution | 7 |
homologous recombination | 7 |
infectious encephalitis | 6 |
significant heterogeneity | 6 |
taken together | 6 |
infections identified | 6 |
nan title | 6 |
myocardial injury | 6 |
com postal | 6 |
asymptomatic cases | 6 |
clinical score | 6 |
chronic malnutrition | 6 |
evolutionary rates | 6 |
acute infection | 6 |
arterial oxygen | 6 |
disease patients | 6 |
cmv pneumonitis | 6 |
hospital length | 6 |
seven years | 6 |
empirical regimen | 6 |
emerging infectious | 6 |
infectious origin | 6 |
hdu icu | 6 |
asymptomatic sars | 6 |
acute kidney | 6 |
type diabetes | 6 |
routine use | 6 |
yap island | 6 |
two different | 6 |
commonly found | 6 |
artery lesions | 6 |
initial treatment | 6 |
analysis revealed | 6 |
second week | 6 |
san diego | 6 |
less likely | 6 |
patient received | 6 |
data suggest | 6 |
water scarcity | 6 |
one hundred | 6 |
infection due | 6 |
negative rt | 6 |
care hospital | 6 |
febrile illness | 6 |
serum ferritin | 6 |
epidemic characteristics | 6 |
laboratory testing | 6 |
social media | 6 |
incidence rate | 6 |
pulmonary fibrosis | 6 |
blood transfusion | 6 |
analysis date | 6 |
higher incidence | 6 |
infect dis | 6 |
oc genotypes | 6 |
mixed infection | 6 |
pneumonia complicating | 6 |
european lineage | 6 |
positive control | 6 |
gene pool | 6 |
increase vaccination | 6 |
using data | 6 |
different clinical | 6 |
overall prevalence | 6 |
oral act | 6 |
sars epidemic | 6 |
negative acute | 6 |
positive antibody | 6 |
clinical progression | 6 |
new challenge | 6 |
low incidence | 6 |
right lower | 6 |
positive test | 6 |
aboriginal children | 6 |
phylogenetic analyses | 6 |
higher percentage | 6 |
human parvovirus | 6 |
care services | 6 |
neutralising antibodies | 6 |
lung fibrosis | 6 |
worse outcomes | 6 |
score index | 6 |
reference laboratory | 6 |
paired serum | 6 |
clarithromycin mg | 6 |
potential risks | 6 |
radiological features | 6 |
first line | 6 |
enzyme immunoassay | 6 |
prevent common | 6 |
may increase | 6 |
acute exacerbations | 6 |
control wells | 6 |
hrv associated | 6 |
fisher exact | 6 |
health professionals | 6 |
significant morbidity | 6 |
positive signals | 6 |
patients developed | 6 |
hbs positive | 6 |
severe lower | 6 |
prophylaxis recipients | 6 |
plaque reduction | 6 |
erythromycin mg | 6 |
hbov positive | 6 |
full access | 6 |
sedimentation rate | 6 |
caseecontrol populations | 6 |
liver dysfunction | 6 |
reported cases | 6 |
critical type | 6 |
antibody titer | 6 |
dose corticosteroid | 6 |
interval ci | 6 |
cell activation | 6 |
children enrolled | 6 |
dengue epidemics | 6 |
active surveillance | 6 |
alternative regimen | 6 |
operational plan | 6 |
nosocomial infection | 6 |
persons aged | 6 |
large numbers | 6 |
molecular assays | 6 |
ventilatory support | 6 |
genomic characterization | 6 |
requiring hospitalization | 6 |
rna polymerase | 6 |
clear evidence | 6 |
disposable non | 6 |
surgical face | 6 |
positive case | 6 |
hbov vp | 6 |
bacterial pathogen | 6 |
whole population | 6 |
first consultation | 6 |
tests performed | 6 |
longitudinal study | 6 |
convalescent patients | 6 |
intravascular coagulation | 6 |
income countries | 6 |
following conditions | 6 |
disseminated intravascular | 6 |
important lessons | 6 |
higher among | 6 |
inflammatory factors | 6 |
health authorities | 6 |
health emergency | 6 |
emerging novel | 6 |
clinically relevant | 6 |
enrolled patients | 6 |
acute covid | 6 |
neurological complications | 6 |
rotavirus group | 6 |
diagnostic tool | 6 |
electronic medical | 6 |
china date | 6 |
acquired infection | 6 |
like symptoms | 6 |
regression model | 6 |
infection compared | 6 |
described previously | 6 |
key role | 6 |
data suggests | 6 |
high quality | 6 |
oral medication | 6 |
higher viral | 6 |
detection method | 6 |
will provide | 6 |
take oral | 6 |
turnaround time | 6 |
evaluated whether | 6 |
currently available | 6 |
patient outcome | 6 |
prevention measures | 6 |
symptom patterns | 6 |
north america | 6 |
two years | 6 |
coronavirus diseases | 6 |
critical role | 6 |
whole genome | 6 |
deep sequencing | 6 |
south africa | 6 |
disease surveillance | 6 |
previous years | 6 |
innate immunity | 6 |
susceptibility tests | 6 |
receptor blockers | 6 |
control study | 6 |
per person | 6 |
pcr detection | 6 |
may lead | 6 |
one month | 6 |
study included | 6 |
publication bias | 6 |
positive rates | 6 |
recently published | 6 |
without fever | 6 |
mass index | 6 |
laboratory confirmed | 6 |
th day | 6 |
occupational risk | 6 |
reported sensitivity | 6 |
mini kit | 6 |
systematic reviews | 6 |
assessment tool | 6 |
alert levels | 6 |
parasite count | 6 |
supplemental oxygen | 6 |
mortality among | 6 |
respiratory diseases | 6 |
outpatient setting | 6 |
following treatment | 6 |
european countries | 6 |
regular exercise | 6 |
gsk vaccines | 6 |
including patients | 6 |
wuhan clinical | 6 |
time course | 6 |
recent travel | 6 |
mass screening | 6 |
cov infections | 6 |
important implications | 6 |
molecular testing | 6 |
comparative agreement | 6 |
also performed | 6 |
also received | 6 |
breast procedures | 6 |
specimens collected | 6 |
wuhan university | 6 |
information regarding | 6 |
deaths per | 6 |
communityacquired pneumonia | 6 |
attributable mortality | 6 |
incidence rates | 6 |
international standard | 6 |
sensitivity analysis | 6 |
human cases | 6 |
infection prevention | 6 |
medical college | 6 |
culture results | 6 |
broad range | 6 |
genotype shift | 6 |
acei arb | 6 |
coverage rates | 6 |
medical illness | 6 |
require hospital | 6 |
asymptomatic carriers | 6 |
cardiac injury | 6 |
pathogens isolated | 6 |
beijing community | 6 |
healthy adults | 6 |
additional studies | 6 |
lambda il | 6 |
global public | 6 |
randomised trial | 6 |
days post | 6 |
exchange transfusion | 6 |
took place | 6 |
relatively low | 6 |
accuracy studies | 6 |
imaging manifestations | 6 |
chikungunya virus | 6 |
mosquito species | 6 |
may persist | 6 |
patients date | 6 |
renal impairment | 6 |
ards patients | 6 |
less common | 6 |
biological incident | 6 |
developed severe | 6 |
mg od | 6 |
possible explanation | 6 |
predicted covid | 6 |
two snps | 6 |
oxygen concentration | 6 |
retrospective analysis | 6 |
ncov infection | 6 |
clinical variables | 6 |
infection may | 6 |
first days | 6 |
rna virus | 6 |
highly sensitive | 6 |
organ failure | 6 |
week later | 6 |
asymptomatic subjects | 6 |
independent predictor | 6 |
antibody prevalence | 6 |
close phylogenetic | 6 |
observational studies | 6 |
brain biopsies | 6 |
immune function | 6 |
patients aged | 6 |
total bilirubin | 6 |
table i | 6 |
per million | 6 |
term follow | 6 |
well known | 6 |
infectious agent | 6 |
effects model | 6 |
runny nose | 6 |
first trimester | 6 |
rsv bronchiolitis | 6 |
slim disease | 6 |
poor outcome | 6 |
study also | 6 |
may benefit | 6 |
creatinine clearance | 6 |
repeated ct | 6 |
rdrp gene | 6 |
zikv may | 6 |
symptomatic cases | 6 |
blood donation | 6 |
asymptomatic individuals | 6 |
potential association | 6 |
critical cases | 6 |
including sars | 6 |
genetic variation | 6 |
acute malnutrition | 6 |
vaccine effectiveness | 6 |
np protein | 6 |
analysis reveals | 6 |
study date | 6 |
metabolic acidosis | 6 |
viral etiology | 6 |
care testing | 6 |
pulmonary imaging | 6 |
epidemiological features | 6 |
viral particles | 6 |
patients presented | 6 |
convalescent phase | 6 |
requiring intensive | 6 |
pathogenic role | 6 |
measles virus | 6 |
necrosis factor | 6 |
vast majority | 6 |
chemical genetics | 6 |
rapid evolution | 6 |
er stress | 6 |
acute bronchitis | 6 |
high concentrations | 6 |
square test | 6 |
testing results | 6 |
also showed | 6 |
studies suggest | 6 |
major outbreak | 6 |
xpert ultra | 6 |
mg qds | 6 |
median cmv | 6 |
computed tomographic | 6 |
interspecies transmission | 6 |
copy ml | 6 |
neurological symptoms | 6 |
rainy season | 6 |
new york | 6 |
salivary swab | 6 |
retrospective case | 6 |
bat sars | 5 |
less sensitive | 5 |
potential confounders | 5 |
enhanced surveillance | 5 |
around times | 5 |
naat platforms | 5 |
mild covid | 5 |
reactive antibodies | 5 |
influenza illness | 5 |
general practice | 5 |
faecal samples | 5 |
complete genomes | 5 |
contact history | 5 |
important cause | 5 |
stranded rna | 5 |
pathogen sequences | 5 |
mp treatment | 5 |
avian infectious | 5 |
ce marked | 5 |
va hmo | 5 |
cardiac complications | 5 |
phylogenetic relationship | 5 |
influenza outbreaks | 5 |
similar results | 5 |
strongly associated | 5 |
quarantine measures | 5 |
spss inc | 5 |
first isolated | 5 |
multicenter study | 5 |
specialist advice | 5 |
promoter polymorphism | 5 |
decision making | 5 |
virtual clinic | 5 |
lung infiltrates | 5 |
baseline characteristics | 5 |
diagnostic criteria | 5 |
pao kpa | 5 |
detectable antibodies | 5 |
association studies | 5 |
african children | 5 |
novel betacoronavirus | 5 |
patient gold | 5 |
microbial causes | 5 |
initial empirical | 5 |
probable cases | 5 |
will require | 5 |
chinese getv | 5 |
among close | 5 |
avian coronaviruses | 5 |
reported case | 5 |
remains unknown | 5 |
provide cover | 5 |
virus outbreak | 5 |
ct images | 5 |
mental status | 5 |
mean value | 5 |
renmin hospital | 5 |
lung tissue | 5 |
decreased incidence | 5 |
cmv therapy | 5 |
comprehensive analysis | 5 |
xpert xpress | 5 |
spread rapidly | 5 |
dna levels | 5 |
infected children | 5 |
treatment strategies | 5 |
samples using | 5 |
health research | 5 |
testing rate | 5 |
phosphate dehydrogenase | 5 |
substitutions site | 5 |
hbov genome | 5 |
roc curve | 5 |
severe coronavirus | 5 |
viral hemorrhagic | 5 |
early course | 5 |
oral fluids | 5 |
two predictive | 5 |
increased mortality | 5 |
creatine kinase | 5 |
medical history | 5 |
peripheral area | 5 |
infection screening | 5 |
critical review | 5 |
metagenomic sequencing | 5 |
four hours | 5 |
population sample | 5 |
mortality due | 5 |
year period | 5 |
radiological worsening | 5 |
trial version | 5 |
reported symptoms | 5 |
least twice | 5 |
cases per | 5 |
research ethics | 5 |
dimer levels | 5 |
high dependency | 5 |
molecular methods | 5 |
adults aged | 5 |
imaging findings | 5 |
several studies | 5 |
study suggests | 5 |
recombinant interferon | 5 |
health concern | 5 |
mg daily | 5 |
less frequently | 5 |
infections among | 5 |
children will | 5 |
first week | 5 |
detection methods | 5 |
outside hubei | 5 |
antimicrobial exposure | 5 |
coronavirus study | 5 |
diagnostic assays | 5 |
small round | 5 |
distinct sars | 5 |
duck aivs | 5 |
differential diagnosis | 5 |
endothelial cells | 5 |
vaccine virus | 5 |
patient age | 5 |
perinatal transmission | 5 |
saliva testing | 5 |
coronavirus spike | 5 |
nitric oxide | 5 |
showed positive | 5 |
clostridium difficile | 5 |
interim guidance | 5 |
acid extraction | 5 |
showed higher | 5 |
public information | 5 |
environmental data | 5 |
fungal pathogens | 5 |
may contribute | 5 |
binding motif | 5 |
prolonged viral | 5 |
stable antibiotic | 5 |
antiretroviral therapy | 5 |
rotavirus infections | 5 |
table ii | 5 |
data regarding | 5 |
highest risk | 5 |
wilcoxon test | 5 |
best practice | 5 |
short time | 5 |
respiratory complications | 5 |
index cases | 5 |
appendix table | 5 |
randomized clinical | 5 |
standard methods | 5 |
infections including | 5 |
severe conditions | 5 |
faecal specimens | 5 |
treatment plan | 5 |
consider cytokine | 5 |
storm syndromes | 5 |
nosocomial transmission | 5 |
pd deficiency | 5 |
bacterial culture | 5 |
results indicate | 5 |
copies per | 5 |
ace receptor | 5 |
hemophagocytic lymphohistiocytosis | 5 |
adjusted odds | 5 |
infected persons | 5 |
like countries | 5 |
ili associated | 5 |
rna viruses | 5 |
rsv infections | 5 |
bloodstream infection | 5 |
empirical antimicrobial | 5 |
streptococcal antigen | 5 |
cell entry | 5 |
three different | 5 |
patients met | 5 |
treatment options | 5 |
single nucleotide | 5 |
less severe | 5 |
transcription loop | 5 |
curve analysis | 5 |
ml tree | 5 |
isolation rooms | 5 |
associated bronchiolitis | 5 |
lesion may | 5 |
severe symptoms | 5 |
posterior oropharyngeal | 5 |
related viruses | 5 |
empirical therapy | 5 |
wuhan city | 5 |
virus may | 5 |
wbc count | 5 |
immunological response | 5 |
risk ratio | 5 |
increasingly recognized | 5 |
biological incidents | 5 |
like particles | 5 |
pattern recognition | 5 |
require corticosteroids | 5 |
ct features | 5 |
preferred first | 5 |
patient population | 5 |
multiple vital | 5 |
rotavirus cases | 5 |
previously well | 5 |
erythrocyte sedimentation | 5 |
case study | 5 |
disease kawasaki | 5 |
adjuvant treatment | 5 |
childhood pneumonia | 5 |
relatively small | 5 |
study highlights | 5 |
influenza incidence | 5 |
specific anti | 5 |
aedes albopictus | 5 |
days prior | 5 |
six days | 5 |
associated diarrhoea | 5 |
mg every | 5 |
fever viruses | 5 |
pandemic strain | 5 |
human reovirus | 5 |
published data | 5 |
neuraminidase inhibitor | 5 |
rif ultra | 5 |
among hiv | 5 |
acute hepatic | 5 |
symptoms including | 5 |
ct findings | 5 |
older adults | 5 |
patients taking | 5 |
foshan city | 5 |
among infants | 5 |
critical covid | 5 |
thin blood | 5 |
dna detection | 5 |
new diagnostic | 5 |
may play | 5 |
independent caseecontrol | 5 |
virus transport | 5 |
zoe global | 5 |
cardiovascular disease | 5 |
viral protein | 5 |
study community | 5 |
secondary cases | 5 |
per ml | 5 |
children months | 5 |
continuous variable | 5 |
single infection | 5 |
zikv rna | 5 |
angiotensin ii | 5 |
biosafety level | 5 |
hepatic injury | 5 |
sample obtained | 5 |
cardiovascular diseases | 5 |
illness may | 5 |
health england | 5 |
early use | 5 |
zhenwei yang | 5 |
stringency index | 5 |
surface protein | 5 |
phase proteins | 5 |
high peak | 5 |
serology index | 5 |
human population | 5 |
legionella pneumophila | 5 |
recombination event | 5 |
secondary infection | 5 |
significantly improved | 5 |
pneumonia severity | 5 |
also provide | 5 |
immunosuppressed patients | 5 |
inflammatory markers | 5 |
studies performed | 5 |
healthcare utilization | 5 |
children without | 5 |
infected people | 5 |
ethical committee | 5 |
empirical antibiotic | 5 |
rapid syndromic | 5 |
prior covid | 5 |
functional polymorphism | 5 |
research committee | 5 |
possible association | 5 |
endemic regions | 5 |
study protocol | 5 |
st lt | 5 |
results show | 5 |
significantly commoner | 5 |
next generation | 5 |
second drug | 5 |
radar system | 5 |
systemic inflammation | 5 |
association study | 5 |
blood tests | 5 |
roche cobas | 5 |
hospital universitario | 5 |
care operational | 5 |
prevalence among | 5 |
high dose | 5 |
final model | 5 |
quantitative real | 5 |
rhinovirus infection | 5 |
wenzhou city | 5 |
influenza seasons | 5 |
cell surface | 5 |
get vaccinated | 5 |
several factors | 5 |
brazil zika | 5 |
full course | 5 |
acute uncomplicated | 5 |
described elsewhere | 5 |
nasal throat | 5 |
master mix | 5 |
positivity rates | 5 |
recombination sites | 5 |
winter season | 5 |
first cases | 5 |
signaling pathways | 5 |
clinical disease | 5 |
specimen collection | 5 |
familial cluster | 5 |
zhejiang province | 5 |
animal species | 5 |
testing using | 5 |
paediatric patients | 5 |
parenteral therapy | 5 |
illness associated | 5 |
breaths per | 5 |
epidemiological data | 5 |
blood sample | 5 |
causing respiratory | 5 |
mild disease | 5 |
serum cholinesterase | 5 |
severe ards | 5 |
respiratory swabs | 5 |
recrudescent fever | 5 |
practice guidelines | 5 |
outpatient department | 5 |
artesunate versus | 5 |
imported falciparum | 5 |
host cells | 5 |
evidence suggests | 5 |
positive infants | 5 |
provide information | 5 |
mass masking | 5 |
significant reduction | 5 |
coronavirus nucleocapsid | 5 |
serum antibody | 5 |
viral dynamics | 5 |
aflp vgi | 5 |
individual populations | 5 |
south american | 5 |
age range | 5 |
china national | 5 |
sars virus | 5 |
epidemiological studies | 5 |
first two | 5 |
igg antibody | 5 |
monkey bite | 5 |
clinical virology | 5 |
patients according | 5 |
hospital care | 5 |
coronavirus causing | 5 |
care corporation | 5 |
confirmed patients | 5 |
final volume | 5 |
influenza vaccines | 5 |
lung damage | 5 |
patients whose | 5 |
clinical sensitivity | 5 |
unit admission | 5 |
laboratory diagnostics | 5 |
acute viral | 5 |
mortality associated | 5 |
laboratory confirmation | 5 |
artemisinin combination | 5 |
serum levels | 5 |
room air | 5 |
site year | 5 |
icu transfer | 5 |
cases compared | 5 |
early transmission | 5 |
mers patients | 5 |
therapy may | 5 |
institutional ethics | 5 |
study shows | 5 |
health services | 5 |
may result | 5 |
bacterial targets | 5 |
urinary streptococcal | 5 |
sexual activity | 5 |
ongoing covid | 5 |
malaria cases | 5 |
third trimester | 5 |
ml urine | 5 |
tissue culture | 5 |
severe enough | 5 |
subtype influenza | 5 |
zikv epidemic | 5 |
american thoracic | 5 |
adverse reactions | 5 |
chinese government | 5 |
uncomplicated pneumonia | 5 |
patients per | 5 |
partial pressure | 5 |
cryptococcus neoformans | 5 |
one third | 5 |
patients within | 5 |
causes severe | 5 |
one possible | 5 |
recurrent wheezing | 5 |
gas measurements | 5 |
official publication | 5 |
antibody results | 5 |
rsv infected | 5 |
potential therapeutic | 5 |
supplementary materials | 5 |
provided evidence | 5 |
first reported | 5 |
male sex | 5 |
cepheid xpert | 5 |
coronavirus nl | 5 |
prognostic role | 5 |
wearing masks | 5 |
generation cephalosporin | 5 |
new influenza | 5 |
hemorrhagic fever | 5 |
pangolin coronavirus | 5 |
tumor necrosis | 5 |
adequately treated | 5 |
molecular detection | 5 |
quantitative pcr | 5 |
southeast asia | 5 |
moderate disease | 5 |
culture supernatants | 5 |
spectrum antibiotics | 5 |
manuscript preparation | 5 |
required mechanical | 5 |
coronavirus outbreak | 5 |
disease date | 5 |
monoclonal antibody | 5 |
rate may | 5 |
percent agreement | 5 |
uk government | 5 |
scoring system | 5 |
aedes mosquitoes | 5 |
table shows | 5 |
functional polymorphisms | 5 |
cell response | 5 |
including age | 5 |
urban areas | 5 |
dependent rna | 5 |
still remains | 5 |
adaptive immunity | 5 |
coronavirus replication | 5 |
oropharyngeal sampling | 5 |
independently associated | 5 |
data will | 5 |
within two | 5 |
oropharyngeal sample | 5 |
term outcomes | 5 |
three novel | 5 |
influenza epidemic | 5 |
children infected | 5 |
average annual | 5 |
virus findings | 5 |
since onset | 5 |
global covid | 5 |
security index | 5 |
pandemic occurs | 5 |
healthcare personnel | 5 |
studies will | 5 |
csf samples | 5 |
measured using | 5 |
trend towards | 5 |
hospital pandemic | 5 |
normal range | 5 |
returning travellers | 5 |
ldh levels | 5 |
molecular evolutionary | 5 |
oral cavity | 5 |
deconfinement strategy | 5 |
specific symptoms | 5 |
may represent | 5 |
days later | 5 |
vaccinees agreed | 5 |
using rt | 5 |
epidemic areas | 5 |
johns hopkins | 5 |
squared test | 5 |
simplex virus | 5 |
novel viruses | 5 |
without respiratory | 5 |
asymptomatic covid | 5 |
vp sequences | 5 |
using real | 5 |
four years | 5 |
patient selection | 4 |
another important | 4 |
pandemic caused | 4 |
host dna | 4 |
convalescent sars | 4 |
two children | 4 |
furosemide treatment | 4 |
remained positive | 4 |
internal genes | 4 |
km wkm | 4 |
hopkins centre | 4 |
front line | 4 |
highly contagious | 4 |
existing chronic | 4 |
british thoracic | 4 |
cold viruses | 4 |
preliminary report | 4 |
imported case | 4 |
hsct recipients | 4 |
future vaccination | 4 |
symptomatic status | 4 |
fungal infections | 4 |
returned travellers | 4 |
influenza type | 4 |
may still | 4 |
structural protein | 4 |
chemical library | 4 |
disease unit | 4 |
bilateral diffuse | 4 |
viral panel | 4 |
study key | 4 |
cardiac troponin | 4 |
asf outbreaks | 4 |
community health | 4 |
selectivity index | 4 |
reaction mixture | 4 |
recombination part | 4 |
myocardial infarction | 4 |
wide wearing | 4 |
fluid testing | 4 |
critical disease | 4 |
software version | 4 |
severely affected | 4 |
may account | 4 |
organ damage | 4 |
independent prognostic | 4 |
chloroquine resistance | 4 |
mutation rates | 4 |
preventing relapse | 4 |
etiological agent | 4 |
potential prognostic | 4 |
fold increase | 4 |
contact group | 4 |
rsv positive | 4 |
korean mers | 4 |
korean children | 4 |
hbc positive | 4 |
prospective observational | 4 |
pneumococcal vaccination | 4 |
high flow | 4 |
factors based | 4 |
control guidance | 4 |
specific circumstances | 4 |
pneumonia without | 4 |
positive controls | 4 |
existing copd | 4 |
mumps virus | 4 |
second case | 4 |
nine patients | 4 |
fatal outcomes | 4 |
distinct cn | 4 |
child health | 4 |
probable cmv | 4 |
particularly important | 4 |
bat coronaviruses | 4 |
prophylaxis users | 4 |
inverse correlation | 4 |
fluorescent signal | 4 |
difference among | 4 |
positivity among | 4 |
reference strains | 4 |
adverse outcome | 4 |
mask wearing | 4 |
viruses identified | 4 |
less frequent | 4 |
key factor | 4 |
people living | 4 |
clinical improvement | 4 |
unexpected pathogens | 4 |
gene source | 4 |
genome sequencing | 4 |
medically attended | 4 |
respiratory secretions | 4 |
systemic symptoms | 4 |
nasopharyngeal specimens | 4 |
also increased | 4 |
cytomegalovirus dna | 4 |
axillary temperatures | 4 |
quality evidence | 4 |
rv infection | 4 |
bacterial causes | 4 |
separate access | 4 |
maximum likelihood | 4 |
still unclear | 4 |
diagnostic methods | 4 |
penicillin susceptibility | 4 |
common symptoms | 4 |
viral aetiology | 4 |
hot spots | 4 |
reach statistical | 4 |
patients also | 4 |
bilateral lung | 4 |
existing disease | 4 |
delay viral | 4 |
detect ors | 4 |
weight kg | 4 |
diseases associated | 4 |
patients reported | 4 |
study patients | 4 |
partial consolidation | 4 |
terry nolan | 4 |
fibrotic stripes | 4 |
recent epidemics | 4 |
developed countries | 4 |
invasive fungal | 4 |
calculated test | 4 |
nasal swab | 4 |
multicenter retrospective | 4 |
pulmonary cytomegalovirus | 4 |
threshold cycle | 4 |
will likely | 4 |
will need | 4 |
icu beds | 4 |
highly variable | 4 |
dares salaam | 4 |
hospitalization rates | 4 |
common finding | 4 |
across different | 4 |
clinical case | 4 |
hospital infection | 4 |
sensu lato | 4 |
possible causes | 4 |
african republic | 4 |
genetics analysis | 4 |
transfusion transmitted | 4 |
case number | 4 |
jialong liu | 4 |
independent ventilation | 4 |
light microscopy | 4 |
stuffy nose | 4 |
endemic area | 4 |
lasting longer | 4 |
cell control | 4 |
specific covid | 4 |
clinical settings | 4 |
higher prevalence | 4 |
hepatitis cases | 4 |
tongji hospital | 4 |
patients hospitalised | 4 |
systems science | 4 |
batcov hku | 4 |
serological survey | 4 |
collaborative study | 4 |
also indicate | 4 |
es salaam | 4 |
earlier studies | 4 |
symptomatic treatment | 4 |
treated group | 4 |
previous findings | 4 |
findings may | 4 |
viral pellets | 4 |
novel sars | 4 |
managed according | 4 |
secondary care | 4 |
amerindian children | 4 |
study site | 4 |
eight countries | 4 |
iga antibody | 4 |
cluster center | 4 |
first month | 4 |
inflammatory responses | 4 |
chest tightness | 4 |
limited access | 4 |
second half | 4 |
likely pathogens | 4 |
viral haemorrhagic | 4 |
preferred regimen | 4 |
chest radiographic | 4 |
studies conducted | 4 |
contact tracing | 4 |
two main | 4 |
virus types | 4 |
coronary arteries | 4 |
usually normal | 4 |
hubei wuhan | 4 |
local transmission | 4 |
biological agents | 4 |
levofloxacin mg | 4 |
paired serological | 4 |
head box | 4 |
patients following | 4 |
abnormal chest | 4 |
autoimmune diseases | 4 |
minority ethnic | 4 |
care admission | 4 |
lymph node | 4 |
routine culture | 4 |
allow us | 4 |
swab specimen | 4 |
igg response | 4 |
hospitalized pediatric | 4 |
patients using | 4 |
chest indrawing | 4 |
regression models | 4 |
infantile gastroenteritis | 4 |
supportive treatment | 4 |
spatial distribution | 4 |
human parainfluenza | 4 |
genetic association | 4 |
cfu ml | 4 |
infantile diarrhoea | 4 |
body mass | 4 |
study covid | 4 |
univariate analyses | 4 |
infected bmcs | 4 |
times daily | 4 |
antibiotic prescriptions | 4 |
reference strain | 4 |
auckland hospital | 4 |
molecular techniques | 4 |
currently levofloxacin | 4 |
preferred choice | 4 |
pcr using | 4 |
cesarean section | 4 |
systemic inflammatory | 4 |
viral factors | 4 |
evidence supporting | 4 |
nursing staff | 4 |
airway inflammation | 4 |
laboratory facilities | 4 |
independent variables | 4 |
japan self | 4 |
without hypertension | 4 |
improved diagnostic | 4 |
amplification reaction | 4 |
saliva collection | 4 |
influenza among | 4 |
initial assessment | 4 |
resistance patterns | 4 |
acute wheezing | 4 |
among hospitalized | 4 |
versus quinine | 4 |
studies included | 4 |
virus might | 4 |
bad health | 4 |
please refer | 4 |
central hospital | 4 |
health facilities | 4 |
including high | 4 |
microbiological surveillance | 4 |
bts hpa | 4 |
fluoroquinolone active | 4 |
common clinical | 4 |
three weeks | 4 |
southern hemisphere | 4 |
i authors | 4 |
amplification test | 4 |
appropriate doses | 4 |
cells per | 4 |
quality control | 4 |
clinical parameters | 4 |
chinese cities | 4 |
open reading | 4 |
cases among | 4 |
swine acute | 4 |
significantly shorter | 4 |
national guidelines | 4 |
old age | 4 |
asf outbreak | 4 |
also included | 4 |
mild moderate | 4 |
hospital staff | 4 |
subsequent testing | 4 |
among young | 4 |
influenza patient | 4 |
pulmonary tb | 4 |
bioinformatics analysis | 4 |
mosquito breeding | 4 |
admission news | 4 |
albumin concentration | 4 |
modelling study | 4 |
routine clinical | 4 |
bacterial flora | 4 |
fungal infection | 4 |
pneumonia within | 4 |
necrotizing enterocolitis | 4 |
five children | 4 |
mild cases | 4 |
great ormond | 4 |
genetic characteristics | 4 |
protein gene | 4 |
different stages | 4 |
patients managed | 4 |
antibodies among | 4 |
suspected malaria | 4 |
two independent | 4 |
endothelial growth | 4 |
dl vs | 4 |
syndrome caused | 4 |
high demand | 4 |
serum creatinine | 4 |
require antibiotics | 4 |
bootstrap value | 4 |
strains isolated | 4 |
rhinovirus detection | 4 |
south china | 4 |
old woman | 4 |
human saliva | 4 |
severe sepsis | 4 |
rich gene | 4 |
influenza epidemics | 4 |
communicable disease | 4 |
vaccination uptake | 4 |
national early | 4 |
replacement therapy | 4 |
routine diagnostics | 4 |
study participants | 4 |
current knowledge | 4 |
coronavirus pandemic | 4 |
symptom reporting | 4 |
american indian | 4 |
stimulated genes | 4 |
febrile convulsions | 4 |
chest signs | 4 |
different genotypes | 4 |
medical research | 4 |
severe forms | 4 |
throughput screening | 4 |
clinical judgement | 4 |
mononuclear cells | 4 |
disease outbreak | 4 |
emc neutralizing | 4 |
adapted cut | 4 |
recent published | 4 |
astrovirus va | 4 |
staff nurses | 4 |
antiviral compounds | 4 |
reporting items | 4 |
alkaline phosphatase | 4 |
paediatric infectious | 4 |
newly discovered | 4 |
first study | 4 |
great threat | 4 |
received prior | 4 |
kgd integrin | 4 |
ausdiagnostics uk | 4 |
commonly used | 4 |
severe outbreaks | 4 |
evolutionary genetics | 4 |
vaccinees thought | 4 |